pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Simponi
drug
save

golimumab

Marketedupdated 3mo ago
by Janssen Biotech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval132 co-mentions · 33 sources
  • drugSimponi Aria66 co-mentions · 33 sources
  • tagOrthopedics66 co-mentions · 33 sources

indications

investigational
IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(0)

nothing on the calendar yet

Trials studying golimumab

  • phase3A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitisactive not recruitingn=84
  • phase2Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Studyactive not recruitingn=8
  • phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitisactive not recruitingn=577
  • phase2A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritiscompletedn=91
  • phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Diseaseactive not recruitingn=703
  • phase3GOLimumab and Methotrexate Versus Methotrexate in Very Early PsAcompletedn=84
  • phase3A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapycompletedn=130
  • phase3A Study of Golimumab in Participants With Active Ankylosing Spondylitiscompletedn=208
more trials →

News(3)

  • Avalo shares spike on skin drug data; BioNTech to cut staff
    Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
    biopharma_dive · 3mo ago
  • STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
    HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
    stat · 3mo ago
  • STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
    A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
    stat · 3mo ago
brand
Simponi
generic
golimumab
indication
Ankylosing Spondylitis (Bekhterev's Disease)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?